Optimi Health Corp. - Common Shares (OPTH) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
56/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$4.74
Trend Context
Mixed / range
Latest briefing
What's happening with OPTH
prnewswire.com29 Jun 2026
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com16 Jun 2026
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optim…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com10 Jun 2026
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
/PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
gurufocus.com
8 Jun 2026
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
